Effect of Allestradiol Combined with Atosiban on Symptom Remission Time and Success Rate of Fetal Preservation in Patients with Threatened Premature Delivery
Objective To investigate the effect of allestradiol combined with atosiban on the symptom remission time and the success rate of fetal preservation in patients with threatened premature delivery. Methods Ninety patients with threatened premature delivery admitted to Zibo City Linzi District Maternal and Child Health Hospital from February 2022 to February 2023 were selected as the study objects,and were divided into a control group and an observation group according to random number table method,with 45 cases in each group. Both groups received general treatment,on this basis,the control group was treated with allestradiol tablets,and the observation group was treated with allestradiol combined with atosiban. The duration of clinical symptom relief,fetal preservation,success rate of fetal protection,perinatal outcome and adverse reactions were compared between the two groups. Results The success rate of the observation group was 97.78％,which was higher than 82.22％ of the control group,the difference was statistically significant (P<0.05). The time of contraction disappearance,abdominal pain disappearance and hemostasis in the observation group were shorter than those in the control group,and the prolongation time of gestational age was longer than that in the control group,the differences between the groups were statistically significant (P<0.05). The neonates Apgar score in the observation group was higher than that in the control group,and the difference was statistically significant (P<0.05). The incidence of perinatal adverse outcomes in the observation group was lower than that in the control group,and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant (P<0.05). Conclusion Allestradiol combined with atosiban can accelerate the relief of clinical symptoms in patients with threatened premature delivery,improve the success rate of fetal protection,and improve the perinatal outcome. The clinical efficacy is significant and the safety is high,and it is worthy of clinical promotion.
NETL
NSTL
万方数据
